NEW YORK (GenomeWeb) – Biocept reported after the close of the market Thursday that its third quarter revenues rose sharply year over year on increased test volume.

The San Diego-based maker of cancer biomarker assays reported total revenues of $164,856 for the three months ended Sept. 30, up from $10,274 for the third quarter of 2014. It said that it accessioned 482 commercial cases during the quarter, nearly five times the 96 commercial cases for the third quarter of 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.